How to use a subgroup analysis: users' guide to the medical literature.
暂无分享,去创建一个
Thomas Agoritsas | John P A Ioannidis | Gordon Guyatt | G. Guyatt | J. Ioannidis | T. Agoritsas | A. Alba | Xin Sun | Ana C Alba | Xin Sun
[2] C H Schmid,et al. An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. , 1998, Statistics in medicine.
[3] J. Ioannidis,et al. Empirical Evaluation of Age Groups and Age-Subgroup Analyses in Pediatric Randomized Trials and Pediatric Meta-analyses , 2012, Pediatrics.
[4] Bess Dawson-Hughes,et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. , 2005, JAMA.
[5] J. Ioannidis. Microarrays and molecular research: noise discovery? , 2005, The Lancet.
[6] M. Buyse,et al. Analysis of clinical trial outcomes: some comments on subgroup analyses. , 1989, Controlled clinical trials.
[7] C. Natanson,et al. The sirens' songs of confirmatory sepsis trials: selection bias and sampling error. , 1998, Critical care medicine.
[8] Jonathan J Deeks,et al. Issues in the selection of a summary statistic for meta‐analysis of clinical trials with binary outcomes , 2002, Statistics in medicine.
[9] B. Schneider. Analysis of clinical trial outcomes: alternative approaches to subgroup analysis. , 1989, Controlled clinical trials.
[10] Scott K Aberegg,et al. Intensive insulin therapy in the medical ICU. , 2006, The New England journal of medicine.
[11] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.
[12] Radcliffe Infirmary,et al. Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients , 1994, BMJ.
[13] Gordon H Guyatt,et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review , 2012, BMJ : British Medical Journal.
[14] J. Hirsh,et al. Sex differences in the antithrombotic effects of aspirin. , 1978, Blood.
[15] Sarah Parish,et al. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.
[16] C. Reid,et al. A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.
[17] Shuler,et al. Study to prospectively evaluate reamed intramedually nails in patients with tibial fractures (S.P.R.I.N.T.): study rationale and design. , 2008 .
[18] Stephen W Lagakos,et al. Statistics in medicine--reporting of subgroup analyses in clinical trials. , 2007, The New England journal of medicine.
[19] M Alan Brookhart,et al. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. , 2006, Archives of internal medicine.
[20] Mohit Bhandari,et al. Study to prospectively evaluate reamed intramedually nails in patients with tibial fractures (S.P.R.I.N.T.): Study rationale and design , 2008, BMC musculoskeletal disorders.
[21] S. Pocock,et al. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems , 2002, Statistics in medicine.
[22] G. Guyatt,et al. The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic review , 2011, BMJ : British Medical Journal.
[23] Xin Sun,et al. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses , 2010, BMJ : British Medical Journal.
[24] Gordon H Guyatt,et al. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. , 2002, International journal of epidemiology.
[25] M. Schaller,et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. , 1998, Critical care medicine.
[26] John P A Ioannidis,et al. What Should the Genome-wide Significance Threshold Be? Empirical Replication of Borderline Genetic Associations Yfor a Full List of Investigators Offering Data and Clarifications See Acknowledgments , 2022 .
[27] C. Furberg,et al. Lessons from overviews of cardiovascular trials. , 1987, Statistics in medicine.
[28] Sangeeta Mehta,et al. Vasopressin versus norepinephrine infusion in patients with septic shock. , 2008, The New England journal of medicine.
[29] J. Slattery,et al. The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis? , 1994, BMJ.
[30] J. Dhainaut,et al. Platelet‐activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double‐blind, placebo‐controlled, multicenter clinical trial , 1994 .
[31] L. Bolognese,et al. RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.